Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


25.02.2019

2 Am J Surg
1 Ann Oncol
2 Ann Surg Oncol
4 BMC Cancer
2 Br J Cancer
4 Breast Cancer Res
1 Breast Cancer Res Treat
2 Breast J
1 Cancer Lett
1 Genes Chromosomes Cancer
1 J Clin Oncol
3 J Natl Cancer Inst
5 N Engl J Med
3 PLoS One
1 Radiology
2 Radiother Oncol


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Surg


  1. Effect of wound complications following mastectomy with reconstruction on breast cancer recurrence.
    Am J Surg. 2019;217:519.
    PubMed     Text format    


  2. The impact of obesity on treatment choices and outcomes in operable breast cancer.
    Am J Surg. 2019;217:478.
    PubMed     Text format    


    Ann Oncol

  3. GUARNERI V, Dieci MV, Bisagni G, Frassoldati A, et al
    De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study.
    Ann Oncol. 2019 Feb 18. pii: 5332974. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  4. HAVEL L, Naik H, Ramirez L, Morrow M, et al
    Impact of the SSO-ASTRO Margin Guideline on Rates of Re-excision After Lumpectomy for Breast Cancer: A Meta-analysis.
    Ann Surg Oncol. 2019 Feb 21. pii: 10.1245/s10434-019-07247.
    PubMed     Text format     Abstract available

  5. PEASE AM, James TA
    ASO Author Reflections: Role of Genomic Assay to Predict Neoadjuvant Chemotherapy Response in Breast Cancer.
    Ann Surg Oncol. 2019 Feb 19. pii: 10.1245/s10434-019-07244.
    PubMed     Text format    


    BMC Cancer

  6. DA COSTA AM, Hashim D, Fregnani JHTG, Weiderpass E, et al
    Overall survival and time trends in breast and cervical cancer incidence and mortality in the Regional Health District (RHD) of Barretos, Sao Paulo, Brazil.
    BMC Cancer. 2018;18:1079.
    PubMed     Text format     Abstract available

  7. VAN DE WIEL HJ, Stuiver MM, May AM, van Grinsven S, et al
    (Cost-)effectiveness of an internet-based physical activity support program (with and without physiotherapy counselling) on physical activity levels of breast and prostate cancer survivors: design of the PABLO trial.
    BMC Cancer. 2018;18:1073.
    PubMed     Text format     Abstract available

  8. LEE E, Luo J, Schumacher FR, Van Den Berg D, et al
    Growth factor genes and change in mammographic density after stopping combined hormone therapy in the California Teachers Study.
    BMC Cancer. 2018;18:1072.
    PubMed     Text format     Abstract available

  9. YE FG, Xia C, Ma D, Lin PY, et al
    Nomogram for predicting preoperative lymph node involvement in patients with invasive micropapillary carcinoma of breast: a SEER population-based study.
    BMC Cancer. 2018;18:1085.
    PubMed     Text format     Abstract available


    Br J Cancer

  10. ESCALA-GARCIA M, Guo Q, Dork T, Canisius S, et al
    Genome-wide association study of germline variants and breast cancer-specific mortality.
    Br J Cancer. 2019 Feb 21. pii: 10.1038/s41416-019-0393.
    PubMed     Text format     Abstract available

  11. MILEVSKIY MJG, Gujral U, Del Lama Marques C, Stone A, et al
    MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer.
    Br J Cancer. 2019 Feb 20. pii: 10.1038/s41416-019-0395.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  12. CAO W, Li J, Hao Q, Vadgama JV, et al
    AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
    Breast Cancer Res. 2019;21:29.
    PubMed     Text format     Abstract available

  13. EMI M, Kim R, Tanabe K, Uchida Y, et al
    Correction to: Targeted therapy against Bcl-2-related proteins in breast cancer cells.
    Breast Cancer Res. 2019;21:26.
    PubMed     Text format     Abstract available

  14. GREER YE, Gilbert SF, Gril B, Narwal R, et al
    MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Breast Cancer Res. 2019;21:27.
    PubMed     Text format     Abstract available

  15. VAN BERCKELAER C, Rypens C, van Dam P, Pouillon L, et al
    Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
    Breast Cancer Res. 2019;21:28.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  16. GUO L, Chen G, Zhang W, Zhou L, et al
    A high-risk luminal A dominant breast cancer subtype with increased mobility.
    Breast Cancer Res Treat. 2019 Feb 19. pii: 10.1007/s10549-019-05135.
    PubMed     Text format     Abstract available


    Breast J

  17. KEMP E, Koczwara B, Turner J, Girgis A, et al
    Internet use and preferences among women living with advanced breast cancer.
    Breast J. 2019 Feb 21. doi: 10.1111/tbj.13203.
    PubMed     Text format     Abstract available

  18. LATOSINSKY S, Jenkyn KMB, Li L, Shariff SZ, et al
    Post-mastectomy radiation in node-positive breast cancer in Ontario.
    Breast J. 2019 Feb 21. doi: 10.1111/tbj.13208.
    PubMed     Text format     Abstract available


    Cancer Lett

  19. BISHOP RT, Marino S, de Ridder D, Allen RJ, et al
    Pharmacological inhibition of the IKKepsilon/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.
    Cancer Lett. 2019 Feb 18. pii: S0304-3835(19)30110.
    PubMed     Text format     Abstract available


    Genes Chromosomes Cancer

  20. RAY M, Ruffalo MM, Bar-Joseph Z
    Construction of integrated microRNA and mRNA immune cell signatures to predict survival of patients with breast and ovarian cancer.
    Genes Chromosomes Cancer. 2019;58:34-42.
    PubMed     Text format     Abstract available


    J Clin Oncol

  21. NITZ U, Gluz O, Clemens M, Malter W, et al
    West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
    J Clin Oncol. 2019 Feb 20:JCO1800028. doi: 10.1200/JCO.18.00028.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  22. NGUYEN B, Veys I, Leduc S, Bareche Y, et al
    Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer.
    J Natl Cancer Inst. 2019 Feb 21. pii: 5355042. doi: 10.1093.
    PubMed     Text format     Abstract available

  23. KRESOVICH JK, Xu Z, O'Brien KM, Weinberg CR, et al
    Methylation-based biological age and breast cancer risk.
    J Natl Cancer Inst. 2019 Feb 22. pii: 5341521. doi: 10.1093.
    PubMed     Text format     Abstract available

  24. HATEM E, Azzi S, El Banna N, He T, et al
    Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2018 Nov 20. pii: 5342932. doi: 10.1093.
    PubMed     Text format     Abstract available


    N Engl J Med

  25. MCCAW ZR, Vassy JL, Wei LJ
    Palbociclib and Fulvestrant in Breast Cancer.
    N Engl J Med. 2019;380:796.
    PubMed     Text format    

  26. JINDEEL A
    Lymphedema after Breast Cancer Treatment.
    N Engl J Med. 2019;380:694.
    PubMed     Text format    

  27. BARDIA A, Mayer IA, Vahdat LT, Tolaney SM, et al
    Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:741-751.
    PubMed     Text format     Abstract available

  28. NAIK RD, Batra A, Gupta VG
    Palbociclib and Fulvestrant in Breast Cancer.
    N Engl J Med. 2019;380:796.
    PubMed     Text format    

  29. TURNER NC, Huang X, Cristofanilli M
    Palbociclib and Fulvestrant in Breast Cancer. Reply.
    N Engl J Med. 2019;380:797.
    PubMed     Text format    


    PLoS One

  30. JOSE V, Fumagalli D, Rothe F, Majjaj S, et al
    Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays.
    PLoS One. 2018;13:e0203346.
    PubMed     Text format     Abstract available

  31. BISWENGER V, Baumann N, Jurschick J, Hackl M, et al
    Characterization of EGF-guided MDA-MB-231 cell chemotaxis in vitro using a physiological and highly sensitive assay system.
    PLoS One. 2018;13:e0203040.
    PubMed     Text format     Abstract available

  32. NAGORSKI J, Allen GI
    Genomic region detection via Spatial Convex Clustering.
    PLoS One. 2018;13:e0203007.
    PubMed     Text format     Abstract available


    Radiology

  33. SKAANE P, Bandos AI, Niklason LT, Sebuodegard S, et al
    Digital Mammography versus Digital Mammography Plus Tomosynthesis in Breast Cancer Screening: The Oslo Tomosynthesis Screening Trial.
    Radiology. 2019 Feb 19:182394. doi: 10.1148/radiol.2019182394.
    PubMed     Text format     Abstract available


    Radiother Oncol

  34. MOUAWAD M, Biernaski H, Brackstone M, Lock M, et al
    Reducing the dose of gadolinium-based contrast agents for DCE-MRI guided SBRT: The effects on inter and intra observer variability for preoperative target volume delineation in early stage breast cancer patients.
    Radiother Oncol. 2019;131:60-65.
    PubMed     Text format     Abstract available

  35. MILANO MT, Katz AW, Zhang H, Huggins CF, et al
    Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade.
    Radiother Oncol. 2019;131:45-51.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: